Seven patients received total excisions (group T), eight underwent partial excisions (group P), and 15 had excisional biopsies (group B). Impacts of the tumor histological grade, the level of the ...

The FDA has approved Voranigo to treat certain patients with grade 2 astrocytoma or oligodendroglioma with select mutations, following surgery. The Food and Drug Administration (FDA) has approved ...

Pilocytic astrocytoma is one of the most common central nervous system glial neoplasms seen in the pediatric population. These tumors occur most frequently in patients between the ages of 0 and 14 ...

The STELLAR Phase 3 clinical trial found that a new treatment approach helped people with a tough-to-treat brain cancer, called grade 3 astrocytoma, live longer. The new treatment is a major step ...

Anaplastic astrocytoma is a rare malignant brain tumor. Astrocytomas are tumors that develop from certain star-shaped brain cells called astrocytes. The disease has been categorized into four ...

MicroRNAs as specific biomarkers for distinguishing between primary and metastatic brain tumors ...

Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Population and uptake' and 'Unit costs' worksheets in the template to reflect local data ...

Q: Who should I consult when I have symptoms like memory loss, headaches and seizures? A: These symptoms can be seen in many disorders that affect the brain, hence you should first consult your ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved vorasidenib for certain patients with astrocytoma or oligodendroglioma. The indication applies ...